FDA fast-tracks approval for three psychedelic drugs targeting depression and PTSD

The FDA's decision to expedite the review process reflects a significant shift towards integrating psychedelics into mainstream mental health treatments. This landmark move may shorten the timeline for these therapies to reach patients and influence future drug development policies. Observers will watch how the clinical trial results and regulatory reviews unfold over the coming months.